GENZYME - THE KING OF THE BIOTECHS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Spekulatius who wrote (273)	5/27/1998 12:37:00 AM
From: Robert Holmes	Read Replies (1) of 410

Don't overlook the potential of RenaGel. This product could very well add $1.00 or more to earnings within the next 2-3 years. Thyrogen will contribute marginally, probably $.30 at best. Cerazyme is expected to continue growth through the end of 1998. Additionally, the company has stated that it hopes to enter into more agreements similar to the Geltex joint venture which is a win-win situation. Genzyme can use its cash position and marketing to obtain rights to products that smaller companies have brought up to or through phase III trials.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next